去甲柔比星
柔红霉素
药代动力学
代谢物
药理学
分配量
活性代谢物
医学
蒽环类
化学
内科学
白血病
阿糖胞苷
癌症
乳腺癌
作者
Jacques Robert,Françoise Rigal‐Huguet,P Hurteloup
标识
DOI:10.1002/hon.2900100207
摘要
We have studied the pharmacokinetics of idarubicin and daunorubicin in a total of 16 leukemic patients treated with one of these drugs associated with aracytine. The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39.0 L/h/m2 for idarubicin versus 38.6 for daunorubicin), total volume of distribution (1756 versus 1725 L/m2) and elimination half-life (42.7 versus 47.4 h). The only metabolites detected were the 13-dihydroderivative of each drug, idarubicinol or daunorubicinol. The elimination half-life of idarubicinol was two times higher than that of daunorubicinol (80.7 versus 37.3 h) which provided an AUC ratio metabolite/parent drug higher for idarubicin than for daunorubicin. In view of the fact that idarubicinol is a much more active metabolite than daunorubicinol, this protracted half-life metabolite can account for the reported higher activity of idarubicin as compared to daunorubicin.
科研通智能强力驱动
Strongly Powered by AbleSci AI